Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Short-term Investments (2016 - 2026)

Gyre Therapeutics has reported Short-term Investments over the past 14 years, most recently at $15.4 million for Q4 2025.

  • Quarterly Short-term Investments rose 3.34% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, up 3.34% year-over-year, with the annual reading at $15.4 million for FY2025, 3.34% up from the prior year.
  • Short-term Investments was $15.4 million for Q4 2025 at Gyre Therapeutics, down from $19.6 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $24.0 million in Q1 2021 and troughed at $2.5 million in Q4 2021.
  • The 3-year median for Short-term Investments is $13.9 million (2021), against an average of $12.8 million.
  • Year-over-year, Short-term Investments tumbled 94.89% in 2021 and then surged 112.44% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $2.5 million in 2021, then soared by 493.37% to $14.9 million in 2024, then grew by 3.34% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Short-term Investments are $15.4 million (Q4 2025), $19.6 million (Q3 2025), and $17.9 million (Q2 2025).